New triple inhaler could offer better asthma control for millions
NCT ID NCT06372496
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a triple-combination inhaler (FF/UMEC/VI) works better than standard dual therapy (ICS/LABA) for adults whose asthma is not well controlled. About 1,366 participants will use either the triple inhaler or their usual treatment for 24 weeks. The main goal is to see if lung function improves more with the triple inhaler.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (a triple-combination inhaler)
What this could lead to
If successful, this could show that the triple-combination inhaler controls asthma better than standard dual therapy, potentially reducing symptoms and improving lung function.
What could go wrong
This is a Phase 4 study comparing existing drugs, so no breakthrough is expected. Results may show only modest benefits, and individual responses can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Centreville, Alabama, 35042, United States
-
GSK Investigational Site
Little Rock, Arkansas, 72205, United States
-
GSK Investigational Site
Newport Beach, California, 92663, United States
-
GSK Investigational Site
Newark, Delaware, 08901, United States
-
GSK Investigational Site
Clearwater, Florida, 33765-2150, United States
-
GSK Investigational Site
Florida City, Florida, 32819, United States
-
GSK Investigational Site
Miami, Florida, 15801, United States
-
GSK Investigational Site
Miami, Florida, 33126, United States
-
GSK Investigational Site
Miami, Florida, 33135, United States
-
GSK Investigational Site
Miami, Florida, 33173, United States
-
GSK Investigational Site
North Miami Beach, Florida, 33169, United States
-
GSK Investigational Site
Palm Springs, Florida, 33406, United States
-
GSK Investigational Site
Port Charlotte, Florida, 33952, United States
-
GSK Investigational Site
Tallahassee, Florida, 32308, United States
-
GSK Investigational Site
Normal, Illinois, 61761, United States
-
GSK Investigational Site
New Orleans, Louisiana, 20852, United States
-
GSK Investigational Site
Bangor, Maine, 04401, United States
-
GSK Investigational Site
Detroit, Michigan, 48202, United States
-
GSK Investigational Site
Warren, Michigan, 48088, United States
-
GSK Investigational Site
Missoula, Montana, 59804, United States
-
GSK Investigational Site
Papillion, Nebraska, 68046, United States
-
GSK Investigational Site
Brick, New Jersey, 08724, United States
-
GSK Investigational Site
Linwood, New Jersey, 08221, United States
-
GSK Investigational Site
New Windsor, New York, 12553, United States
-
GSK Investigational Site
Asheville, North Carolina, 28801, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28273, United States
-
GSK Investigational Site
Greenville, North Carolina, 27834, United States
-
GSK Investigational Site
Winston-Salem, North Carolina, 27104, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45231, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19140, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15241, United States
-
GSK Investigational Site
Rock Hill, South Carolina, 29732, United States
-
GSK Investigational Site
Spartanburg, South Carolina, 29303, United States
-
GSK Investigational Site
Beaumont, Texas, 77701, United States
-
GSK Investigational Site
Dallas, Texas, 75225, United States
-
GSK Investigational Site
Bellingham, Washington, 98225, United States
-
GSK Investigational Site
Buenos Aires, C1128AAF, Argentina
-
GSK Investigational Site
Buenos Aires, C1192AAW, Argentina
-
GSK Investigational Site
Buenos Aires, C1425BEN, Argentina
-
GSK Investigational Site
Buenos Aires, FVH1425, Argentina
-
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, 1012, Argentina
-
GSK Investigational Site
Concepción del Uruguay, 3260, Argentina
-
GSK Investigational Site
Córdoba, X5003DCE, Argentina
-
GSK Investigational Site
Formosa, 3600, Argentina
-
GSK Investigational Site
Lujan de Cuyo, 5509, Argentina
-
GSK Investigational Site
Luján, 6700, Argentina
-
GSK Investigational Site
Mar del Plata, 7600, Argentina
-
GSK Investigational Site
Mendoza, 5500, Argentina
-
GSK Investigational Site
Mendoza, 5577, Argentina
-
GSK Investigational Site
Mendoza, M5500, Argentina
-
GSK Investigational Site
Quilmes, 1878, Argentina
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Rosario, S2000 DEJ, Argentina
-
GSK Investigational Site
Rosario, S2000DBS, Argentina
-
GSK Investigational Site
San Juan Bautista, 1888, Argentina
-
GSK Investigational Site
San Miguel de Tucumán, T4000AXL, Argentina
-
GSK Investigational Site
Santa Fe, 3000, Argentina
-
GSK Investigational Site
Bruce, Australian Capital Territory, 2617, Australia
-
GSK Investigational Site
Blacktown, New South Wales, 2148, Australia
-
GSK Investigational Site
Coffs Harbour, New South Wales, 2450, Australia
-
GSK Investigational Site
Kanwal, New South Wales, 2259, Australia
-
GSK Investigational Site
Sydney, New South Wales, 2035, Australia
-
GSK Investigational Site
Brisbane, Queensland, 4006, Australia
-
GSK Investigational Site
Osborne Park, Western Australia, 6017, Australia
-
GSK Investigational Site
Spearwood, Western Australia, 6163, Australia
-
GSK Investigational Site
Windsor, Ontario, N8X 1T3, Canada
-
GSK Investigational Site
Trois-Rivières, Quebec, G9A 4P3, Canada
-
GSK Investigational Site
Chancheng District, Foshan City, 528031, China
-
GSK Investigational Site
Liwan District, Guangzhou, 510160, China
-
GSK Investigational Site
North Street, Jiangmen City, 52900, China
-
GSK Investigational Site
Nanshan District, 518067, China
-
GSK Investigational Site
Zhuhai, 519099, China
-
GSK Investigational Site
Fukuoka, 802-0083, Japan
-
GSK Investigational Site
Fukuoka, 807-8555, Japan
-
GSK Investigational Site
Fukuoka, 816-0813, Japan
-
GSK Investigational Site
Fukuoka, 820-8505, Japan
-
GSK Investigational Site
Fukuoka, 832-0059, Japan
-
GSK Investigational Site
Gifu, 509-6134, Japan
-
GSK Investigational Site
Hiroshima, 730-0013, Japan
-
GSK Investigational Site
Hiroshima, 730-0853, Japan
-
GSK Investigational Site
Hiroshima, 733-0002, Japan
-
GSK Investigational Site
Hyōgo, 651-0053, Japan
-
GSK Investigational Site
Kagawa, 761-8073, Japan
-
GSK Investigational Site
Kagoshima, 890-0053, Japan
-
GSK Investigational Site
Kanagawa, 252-0143, Japan
-
GSK Investigational Site
Kumamoto, 860-8556, Japan
-
GSK Investigational Site
Kumamoto, 862-0965, Japan
-
GSK Investigational Site
Matsuyama, 790-0925, Japan
-
GSK Investigational Site
Miyagi, 980-0871, Japan
-
GSK Investigational Site
Miyazaki, 880-2112, Japan
-
GSK Investigational Site
Miyazaki, 889-4304, Japan
-
GSK Investigational Site
Nagaoka-Shi, 940-0087, Japan
-
GSK Investigational Site
Niigata, 950-0088, Japan
-
GSK Investigational Site
Okawa-shi, 831-0016, Japan
-
GSK Investigational Site
Ōita, Japan
-
GSK Investigational Site
Shinjuku-kuTokyo, 160-0021, Japan
-
GSK Investigational Site
Tokyo, 105-0001, Japan
-
GSK Investigational Site
Tokyo, 142-8666, Japan
-
GSK Investigational Site
Tokyo, 145-0063, Japan
-
GSK Investigational Site
Tokyo, 157-0066, Japan
-
GSK Investigational Site
Tokyo, 160-0017, Japan
-
GSK Investigational Site
Tokyo, 173-8606, Japan
-
GSK Investigational Site
Yokohama, 223-0053, Japan
-
GSK Investigational Site
Busan, 602 702, South Korea
-
GSK Investigational Site
Daegu, 41404, South Korea
-
GSK Investigational Site
Seongnam-si Gyeonggi-do, 13620, South Korea
-
GSK Investigational Site
Seoul, 02841, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 07061, South Korea
-
GSK Investigational Site
Seoul, 133-792, South Korea
-
GSK Investigational Site
Seoul, 158-710, South Korea
-
GSK Investigational Site
Seoul, 5030, South Korea
-
GSK Investigational Site
Suwon Kyunggi-do, 16499, South Korea
-
GSK Investigational Site
Kaohsiung City, 807, Taiwan
-
GSK Investigational Site
Taichung, 40447, Taiwan
-
GSK Investigational Site
Taichung, 407219, Taiwan
-
GSK Investigational Site
Taipei, 10002, Taiwan